[go: up one dir, main page]

DE60007960T2 - Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen - Google Patents

Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen Download PDF

Info

Publication number
DE60007960T2
DE60007960T2 DE60007960T DE60007960T DE60007960T2 DE 60007960 T2 DE60007960 T2 DE 60007960T2 DE 60007960 T DE60007960 T DE 60007960T DE 60007960 T DE60007960 T DE 60007960T DE 60007960 T2 DE60007960 T2 DE 60007960T2
Authority
DE
Germany
Prior art keywords
compounds
benzodiazepine
benzodiazepines
disorders
apoptotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60007960T
Other languages
English (en)
Other versions
DE60007960D1 (de
Inventor
D Glick
W Opipari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan Ann Arbor filed Critical University of Michigan Ann Arbor
Application granted granted Critical
Publication of DE60007960D1 publication Critical patent/DE60007960D1/de
Publication of DE60007960T2 publication Critical patent/DE60007960T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60007960T 1999-04-30 2000-04-27 Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen Expired - Lifetime DE60007960T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13176199P 1999-04-30 1999-04-30
US16551199P 1999-11-15 1999-11-15
US19185500P 2000-03-24 2000-03-24
PCT/US2000/011599 WO2000066106A2 (en) 1999-04-30 2000-04-27 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis

Publications (2)

Publication Number Publication Date
DE60007960D1 DE60007960D1 (de) 2004-03-04
DE60007960T2 true DE60007960T2 (de) 2004-10-21

Family

ID=27384197

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60007960T Expired - Lifetime DE60007960T2 (de) 1999-04-30 2000-04-27 Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen
DE60042425T Expired - Lifetime DE60042425D1 (de) 1999-04-30 2000-04-27 Verwendung von Benzodiazepinen zur Behandlung von autoimmunischen Krankheiten, Entzündungen, Neoplasien, viralen Infektionen und Atherosklerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60042425T Expired - Lifetime DE60042425D1 (de) 1999-04-30 2000-04-27 Verwendung von Benzodiazepinen zur Behandlung von autoimmunischen Krankheiten, Entzündungen, Neoplasien, viralen Infektionen und Atherosklerosis

Country Status (13)

Country Link
US (5) US7125866B1 (de)
EP (4) EP2359831A3 (de)
JP (1) JP5127096B2 (de)
AT (2) ATE258439T1 (de)
AU (2) AU782447C (de)
CA (1) CA2372150C (de)
DE (2) DE60007960T2 (de)
DK (1) DK1143946T3 (de)
ES (1) ES2214273T3 (de)
IL (2) IL146222A0 (de)
MX (1) MXPA01011052A (de)
PT (1) PT1143946E (de)
WO (1) WO2000066106A2 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2785803B1 (fr) * 1998-11-17 2005-03-25 Sanofi Sa Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
DE60007960T2 (de) * 1999-04-30 2004-10-21 Univ Michigan Ann Arbor Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7572788B2 (en) * 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
WO2003015703A2 (en) * 2001-08-15 2003-02-27 The Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
PL370176A1 (en) 2001-11-13 2005-05-16 3-Dimensional Pharmaceuticals, Inc. Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
GB0221923D0 (en) * 2002-09-20 2002-10-30 Arrow Therapeutics Ltd Chemical compounds
JP4719466B2 (ja) 2002-09-20 2011-07-06 アロー セラピューティクス リミテッド ベンゾジアゼピン誘導体およびそれらを含有する医薬組成物
CA2524394C (en) * 2003-05-01 2011-07-12 The Regents Of The University Of Michigan Novel benzodiazepine compounds, compositions and uses thereof
EP2633856A3 (de) * 2003-05-09 2014-01-01 The Trustees of The University of Pennsylvania ATP-Citrat-Lyasehemmer zur Behandlung von Krebs
JP2007516404A (ja) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ， インコーポレイテッド 光学点火されたかまたは電気点火された内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット
US20050120397A1 (en) * 2003-11-24 2005-06-02 Hermann Steller Compounds and methods for regulation of spermatid differentiation
US20070293482A1 (en) * 2004-03-19 2007-12-20 Novartis Pharmaceuticals Corporation Process for Preparing Benzodiazepines
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP2246086A3 (de) 2004-08-12 2012-11-21 Alexza Pharmaceuticals, Inc. Aerosolverabreichungsvorrichtung mit Schlag gezündete Heizeinheit
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2006074358A1 (en) 2005-01-03 2006-07-13 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP1893218A4 (de) * 2005-06-01 2011-01-12 Univ Michigan Ungelöste benzodiazepin-zusammensetzungen und verfahren
US20090221559A1 (en) * 2005-09-02 2009-09-03 Jean-Francois Bonfanti Benzodiazepines as hcv inhibitors
CN101267825B (zh) * 2005-09-19 2011-12-28 阿罗治疗有限公司 治疗丙型肝炎感染的苯并二氮杂*衍生物
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
NZ568254A (en) * 2005-11-01 2011-06-30 Univ Michigan 1,4-Benzodiazepine-2,5-diones for regulating cell death and treating autoimmune diseases
KR20120034772A (ko) 2006-03-29 2012-04-12 에프. 호프만-라 로슈 아게 Ｍｇｌｕｒ2 길항물질로서의 피리딘 및 피리미딘 유도체
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
MX2008015488A (es) 2006-06-09 2009-02-12 Univ Michigan Composiciones y metodos relacionados con compuestos novedosos y objetivos de los mismos.
US20100021928A1 (en) * 2006-06-26 2010-01-28 Technion Research & Development Foundation Ltd. Methods and kits for diagnosing cancer
WO2008099020A1 (en) * 2007-02-16 2008-08-21 Tibotec Pharmaceuticals Ltd. 1,1-dioxo-1-thia-5,10-diazadibenzocycloheptenes useful as hepatitis c virus inhibitors
WO2008112553A1 (en) * 2007-03-09 2008-09-18 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP2121088B1 (de) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Erhitzungseinheit zur verwendung in einer arzneimittelabgabevorrichtung
EP2146722A4 (de) * 2007-05-10 2011-08-03 Amr Technology Inc Aryl- und heteroarylsubstituierte tetrahydrobenzo-1,4-diazepine und ihre verwendung zur blockierung der wiederaufnahme von norepinephrin, dopamin und serotonin
MX2010002732A (es) 2007-09-14 2010-06-02 Univ Michigan Inhibidores de f1f0-atpasa y metodos relacionados.
AU2008323945B2 (en) 2007-11-06 2013-11-28 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
GB2456562A (en) * 2008-01-18 2009-07-22 Petra Technology Ltd Treatment of HIV/AIDS
EP2145873A1 (de) * 2008-06-17 2010-01-20 Commissariat A L'energie Atomique Neue Verbindungen, die eine Schutzaktivität gegen die Wirkung von Toxinen und Viren über einen intrazellulären Wirkungsmechanismus entfalten
EP2352724B1 (de) 2008-09-11 2015-04-22 The Regents of the University of Michigan Arylguanidine-f1f0-aptase inhibitoren und deren therapeutischen verwendung
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US9075060B2 (en) 2009-06-16 2015-07-07 Technion Research & Development Foundation Limited Methods for diagnosing oral or oral-pharyngeal cancer
EP2470020A4 (de) * 2009-09-18 2013-03-13 Univ Michigan Benzodiazepinonverbindungen und behandlungsverfahren damit
WO2011062765A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
AU2010322287B2 (en) 2009-11-17 2014-04-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
CN102190631B (zh) * 2010-03-10 2014-10-29 中国人民解放军63975部队 苯二氮卓化合物的制备方法
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
US9133139B2 (en) 2012-09-21 2015-09-15 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
JP2015529253A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｎｏｔｃｈ阻害剤としてのフルオロアルキルおよびフルオロシクロアルキル１，４−ベンゾジアゼピノン化合物
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
US9273075B2 (en) 2012-09-21 2016-03-01 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
WO2014047393A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors
US9242941B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
EP2897960B1 (de) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclische/heterocyclische verbindungen als notch-inhibitoren
EP2981267A1 (de) 2013-04-04 2016-02-10 Bristol-Myers Squibb Company Kombinationstherapie zur behandlung von proliferativen erkrankungen
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
AU2016242861B2 (en) 2015-03-31 2020-08-20 Enanta Phamraceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
RS63653B1 (sr) 2015-07-22 2022-11-30 Enanta Pharm Inc Benzodiazepinski derivati kao inhibitori rsv
CN108699077B (zh) 2016-01-15 2021-03-02 英安塔制药有限公司 作为rsv抑制剂的杂环化合物
CN105693634B (zh) * 2016-03-17 2018-12-11 清华大学 化合物及其用途
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
MX2019003790A (es) 2016-10-04 2019-09-26 Enanta Pharm Inc Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
CN110809472B (zh) 2017-02-16 2023-05-23 英安塔制药有限公司 用于制备苯二氮䓬衍生物的方法
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
JP7198811B2 (ja) 2017-09-29 2023-01-04 エナンタ ファーマシューティカルズ インコーポレイテッド Ｒｓｖ阻害剤としての組み合わせ医薬剤
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
EP3710009B1 (de) 2017-11-13 2025-07-30 Enanta Pharmaceuticals, Inc. Verfahren zur auflösung von benzodiazepin-2-on und benzoazepin-2-on-derivaten
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
KR102852740B1 (ko) 2018-02-02 2025-08-29 알렉스자 파마스티칼즈, 인크. 전기적 응축 에어로졸 디바이스
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2019199908A1 (en) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
BR112021018335A2 (pt) 2019-03-18 2021-11-23 Enanta Pharm Inc Derivados de benzodiazepina como inibidores de rsv
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AU2020357452A1 (en) 2019-10-04 2022-05-12 Enanta Pharmaceuticals, Inc Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
GB202010409D0 (en) * 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
IL305189A (en) 2021-02-26 2023-10-01 Enanta Pharm Inc Heterocyclic antiviral compounds
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
CN117263873A (zh) * 2022-06-15 2023-12-22 复旦大学 1,4-苯二氮䓬类化合物及其在制备抗肿瘤药物中的用途

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2457405A (en) * 1945-09-25 1948-12-28 Monsanto Chemicals Halo nitroparaffin modified aminoplasts
DE1810423U (de) 1960-01-05 1960-04-28 Kaiserslautern Guss Armatur Schornsteinreinigungsverschluss.
US3261828A (en) 1962-10-04 1966-07-19 Hoffmann La Roche 3h-1,4-benzodiazepine-2,5(1h,4h)-dione compounds
US3374264A (en) * 1962-10-04 1968-03-19 Hoffmann La Roche N-haloacetyl-anthranilic acids and esters
FR1497456A (fr) * 1964-06-15 1967-10-13 Clin Byla Ets Ortho-amino aryl cétimines, composés hétérocycliques qui s'y rattachent et prépaation de ces divers corps
NO120269B (de) * 1965-11-02 1970-09-28 Hoffmann La Roche
US3384635A (en) 1966-09-28 1968-05-21 Sterling Drug Inc 1, 4-benzodiazepine derivatives
US3415814A (en) 1966-09-28 1968-12-10 Sterling Drug Inc 4-(cyclopropylmethyl)-3h-1,4-benzodiazepine-2,5(1h,4h)-dione
AT280290B (de) * 1967-11-24 1970-04-10 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen 1-Phenyl-4-alkyl-3H-1,4-benzodiazepin-2,5-[1H,4H]-dionen
USRE30293E (en) * 1969-03-18 1980-06-03 Knoll A.G. Process for preparing 1,5-benzodiazepine-2-ones
US4108852A (en) * 1969-03-18 1978-08-22 Knoll Ag. Process for preparing 1,5-benzodiazepine-2-ones
CH559729A5 (de) 1970-10-23 1975-03-14 Hoechst Ag
GB1324469A (en) * 1970-10-28 1973-07-25 Knoll Ag Derivatives of benzodiazepines
US3806594A (en) * 1972-11-24 1974-04-23 Abbott Lab Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium
ZA7469B (en) * 1973-01-16 1974-11-27 J Voorhees Compositions and treatment of proliferative skin diseases with-c-amp analogs
IE38931B1 (en) 1973-03-09 1978-07-05 Lipha Triazolobenzodiazepines
US4110327A (en) * 1974-05-09 1978-08-29 Toyama Chemical Co., Ltd. 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4076823A (en) 1977-08-18 1978-02-28 E. R. Squibb & Sons, Inc. Triazolo-2,4-benzodiazepines
JPS59112984A (ja) * 1982-12-21 1984-06-29 Shionogi & Co Ltd １，４−ベンゾジアゼピン誘導体
US4495101A (en) 1983-04-28 1985-01-22 American Home Products Corporation Antiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivatives
US4551480A (en) * 1983-06-21 1985-11-05 Stiefel Laboratories, Inc. Compositions for the treatment of psoriasis
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5004741A (en) * 1984-06-26 1991-04-02 Merck & Co., Inc. Methods of antagonizing CCK or gastrin with benzodiazepine analogs
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
DE3435974A1 (de) * 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
FR2591596B1 (fr) * 1985-12-13 1988-09-09 Roussel Uclaf Nouvelles 4h-triazolo(4,3-a)(1,4)benzodiazepines, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4751223A (en) 1986-10-14 1988-06-14 Hoechst-Roussel Pharmaceuticals, Inc. Antiinflammatory and analgesic aminoalkyl tetracyclic benzodiazepines
US4898861A (en) * 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
US5147872A (en) * 1987-06-09 1992-09-15 Golwyn Daniel H Treatment of immunologically based disorders, specifically psoriasis
US4970207A (en) * 1988-07-07 1990-11-13 Fujisawa Pharmaceutical Company, Ltd. Benzodiazepine derivatives
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5041438A (en) 1989-10-30 1991-08-20 Hoffmann-La Roche Inc. Method for treating retroviral infections with benzodiazepine compounds
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
JPH05502179A (ja) 1990-02-28 1993-04-22 メドトロニック　インコーポレーテッド 管状器官内薬剤溶出装具
ATE145208T1 (de) * 1990-07-06 1996-11-15 Yoshitomi Pharmaceutical Kondensierte thiophenverbindungen und deren verwendung
GB9015879D0 (en) * 1990-07-19 1990-09-05 Fujisawa Pharmaceutical Co Benzodiazepine derivatives
BR9200951A (pt) * 1991-03-21 1992-11-17 Hoffmann La Roche Compostos, processo para sua producao,preparacoes farmaceuticas e uso
JPH07504908A (ja) 1992-03-16 1995-06-01 メルク　シヤープ　エンド　ドーム　リミテツド ベンゾジアゼピン誘導体，該誘導体を含有する組成物及び治療におけるその使用
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
GB9307527D0 (en) * 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5391566A (en) * 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5444092A (en) * 1994-07-20 1995-08-22 Collins; Jerry Method and composition for treating psoriasis
US5763437A (en) * 1994-07-29 1998-06-09 Fujisawa Pharmaceutical Co., Ltd. Benzodiazepine derivatives
CA2195973A1 (en) * 1994-08-18 1996-02-29 David A. Claremon N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
WO1996036361A1 (en) 1995-05-18 1996-11-21 The Regents Of The University Of Michigan Dna binding antibodies
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
US5692337A (en) * 1995-06-07 1997-12-02 Motz, Jr.; Ronald W. Collapsible plant shelter
US5962337A (en) 1995-06-29 1999-10-05 Pharmacopeia, Inc. Combinatorial 1,4-benzodiazepin-2,5-dione library
RU2096044C1 (ru) 1995-07-19 1997-11-20 Малое предприятие "Ветта" Ветеринарный имплантируемый препарат для регулирования биологического ритма животных
US5776946A (en) 1995-08-28 1998-07-07 Mcgeer; Patrick L. Peripheral benzodiazepine receptor ligands as antiinflammatory agents
JP2001520636A (ja) 1995-08-30 2001-10-30 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 慢性炎症性疾患における細胞蓄積の治療
ATE214055T1 (de) * 1995-09-21 2002-03-15 Inst Med Molecular Design Inc Retinoid-potenzierende verbindungen
US6579854B1 (en) * 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
US7351421B2 (en) * 1996-11-05 2008-04-01 Hsing-Wen Sung Drug-eluting stent having collagen drug carrier chemically treated with genipin
WO1998025911A1 (en) * 1996-12-10 1998-06-18 Zeria Pharmaceutical Co., Ltd. 1,5-benzodiazepine derivatives
US6074859A (en) * 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
DE69832984T2 (de) * 1997-10-08 2006-09-21 Isotechnika, Inc., Edmonton DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
US6100254A (en) * 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
FR2772271B1 (fr) 1997-12-11 2000-09-01 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US6206914B1 (en) * 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US20030044776A1 (en) 1998-09-25 2003-03-06 James A. Dykens Compositions and methods for identifying agents that alter mitochondrial permeability transition pores
FR2785803B1 (fr) 1998-11-17 2005-03-25 Sanofi Sa Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
US7175953B2 (en) * 1999-04-09 2007-02-13 Institute Fuer Diagnostik Forschung Short-warp peptide-dye conjugate as contrast agent for optical diagnostic
US7572788B2 (en) * 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20050113460A1 (en) 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
DE60007960T2 (de) 1999-04-30 2004-10-21 Univ Michigan Ann Arbor Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen
US7276348B2 (en) * 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2001004103A1 (en) 1999-07-13 2001-01-18 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
US6524623B1 (en) * 1999-11-12 2003-02-25 Milton Hodosh Therapeutic compositions and methods of use thereof
EP1280559B1 (de) * 2000-05-11 2006-03-08 Eastman Chemical Company Acylierte zyklodextrin guest-inklusion komplexe
US20020048566A1 (en) * 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
US20020128208A1 (en) 2000-12-15 2002-09-12 Snyder James P. Nonpeptide agonists and antagonists of vasopressin receptors
US7250410B2 (en) * 2001-06-07 2007-07-31 Via Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
WO2003015703A2 (en) 2001-08-15 2003-02-27 The Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US6916813B2 (en) * 2001-12-10 2005-07-12 Bristol-Myers Squibb Co. (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
AU2003276648A1 (en) * 2002-06-17 2003-12-31 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase
US7150433B2 (en) * 2002-08-16 2006-12-19 Toyota Motor Sales, U.S.A., Inc. Aircraft bolster trays
AU2003295402A1 (en) * 2002-11-06 2004-06-03 Bristol-Myers Squibb Company Acyl guanidine compounds and use thereof
US20040087489A1 (en) * 2002-11-06 2004-05-06 Antonio Ruiz Compositions and methods for the treatment of mycobacterial infections
JP2006510634A (ja) * 2002-12-03 2006-03-30 ヴェラ ファーマスーティカルズ インコーポレイテッド １−（３，４−ジメトキシフェニル）−４−メチル−５−エチル−７−メトキシ−８−ヒドロキシ−５ｈ−２，３−ベンゾジアゼピンの製薬組成物及びその用途
DE60329030D1 (de) 2002-12-04 2009-10-08 Ore Pharmaceuticals Inc Melanocortin-rezeptormodulatoren
CA2524394C (en) 2003-05-01 2011-07-12 The Regents Of The University Of Michigan Novel benzodiazepine compounds, compositions and uses thereof
US7351241B2 (en) * 2003-06-02 2008-04-01 Carl Zeiss Meditec Ag Method and apparatus for precision working of material
US20050272723A1 (en) 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
TW200612948A (en) 2004-07-01 2006-05-01 Synta Pharmaceuticals Corp 2-substituted heteroaryl compounds
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2006074358A1 (en) 2005-01-03 2006-07-13 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP1893218A4 (de) 2005-06-01 2011-01-12 Univ Michigan Ungelöste benzodiazepin-zusammensetzungen und verfahren
WO2007050587A2 (en) 2005-10-26 2007-05-03 The Regents Of The University Of Michigan Therapeutic compositions and methods
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
NZ568254A (en) * 2005-11-01 2011-06-30 Univ Michigan 1,4-Benzodiazepine-2,5-diones for regulating cell death and treating autoimmune diseases
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
MX2008015488A (es) 2006-06-09 2009-02-12 Univ Michigan Composiciones y metodos relacionados con compuestos novedosos y objetivos de los mismos.
WO2008112553A1 (en) * 2007-03-09 2008-09-18 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
MX2010002732A (es) 2007-09-14 2010-06-02 Univ Michigan Inhibidores de f1f0-atpasa y metodos relacionados.
AU2008323945B2 (en) 2007-11-06 2013-11-28 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions

Also Published As

Publication number Publication date
DE60042425D1 (de) 2009-07-30
WO2000066106A2 (en) 2000-11-09
EP2062583B1 (de) 2012-12-26
US8809323B2 (en) 2014-08-19
ES2214273T3 (es) 2004-09-16
WO2000066106A9 (en) 2002-04-18
US20010016583A1 (en) 2001-08-23
EP1143946B1 (de) 2004-01-28
US7125866B1 (en) 2006-10-24
ATE433752T1 (de) 2009-07-15
US20090012065A1 (en) 2009-01-08
US7220739B2 (en) 2007-05-22
AU2005227385B2 (en) 2008-12-11
EP2359831A3 (de) 2012-02-01
EP1398033B1 (de) 2009-06-17
AU2005227385A1 (en) 2005-12-01
DE60007960D1 (de) 2004-03-04
AU782447C (en) 2006-07-13
EP2062583A2 (de) 2009-05-27
AU2005227385C1 (en) 2009-05-21
EP1143946A2 (de) 2001-10-17
DK1143946T3 (da) 2004-06-07
ATE258439T1 (de) 2004-02-15
MXPA01011052A (es) 2002-11-22
JP5127096B2 (ja) 2013-01-23
PT1143946E (pt) 2004-05-31
AU4680200A (en) 2000-11-17
EP1398033A2 (de) 2004-03-17
US20140038947A1 (en) 2014-02-06
WO2000066106A3 (en) 2001-08-16
EP2062583A3 (de) 2009-12-30
CA2372150A1 (en) 2000-11-09
EP2359831A2 (de) 2011-08-24
EP1398033A3 (de) 2004-06-30
AU782447B2 (en) 2005-07-28
JP2002543121A (ja) 2002-12-17
IL146222A (en) 2008-06-05
IL146222A0 (en) 2002-07-25
US20070036854A1 (en) 2007-02-15
CA2372150C (en) 2011-08-30

Similar Documents

Publication Publication Date Title
DE60007960T2 (de) Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen
ATE208777T1 (de) (a)-annelierte pyrrolderivate und deren anwendung in der pharmazie
EE04799B1 (et) Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
EE200200684A (et) Piperasiini derivaadid ja nende kasutamine põletikuvastaste vahenditena
FI971776L (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
AR008630A1 (es) Indol-3-glioxilamidas n-sustituidas con efecto antiasmatico, antialergico e inmunosupresor/inmunomodulador, procedimientos para su preparacion, suutilizacion farmaceutica y las composiciones farmaceuticas que las contienen.
BR9814592A (pt) "compostos azopolicìclicos condensados com arila"
EP1595543A3 (de) Antineoplastische pharmazeutische Zusammensetzungen enthaltend Taurolidin oder Taurultam und 5-Fluorouracil
EP0948341A4 (de) Derivate von phospholipide medikamenten
DE69724777D1 (de) Pentafluorobenzensulfonamiden und analoge
CA2326970A1 (en) Acetylene derivatives as anti-inflammatory/analgesic agents
ATE223917T1 (de) (a)-annelierte pyrrolderivate und deren anwendung in der pharmazie
CY1105225T1 (el) Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας
DK0929565T3 (da) Nitratestere af corticoidforbindelser og farmaceutiske anvendelser deraf
TR199801268T2 (xx) Ta�ikinin antagonistleri olarak 3-Azetidinilalkilpiperidinler veya pirolidinler.
ATE236147T1 (de) Derivate von flavonen, xanthonen und kumarinen
PT628033E (pt) Derivados de benzodiazepina uteis como antagonistas dos receptores-cck
ATE251624T1 (de) Granulatimide-derivate zur behandlung von krebs
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
AR013844A1 (es) Compuestos derivados de 3-oxo-pirido[1,2-a] bencimidazol-4-carboxamida sustituidos en posicion 5 con alquilo que contiene heteroatomo,- y composiciones farmaceuticas que los comprenden.
DE69936186D1 (de) Dihydroartemisinin-Formulierung zur Behandlung von verschiedenen Typen von Malaria
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
ATE263179T1 (de) Kohlenhydrate derivate und die enthaltende zusammensetzungen
BR9714408A (pt) Heterocicliluracilas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition